Berenberg Ups Sobi Forecasts After Q2 Results Showed 'Excellent Momentum'

06:25 AM EDT, 07/17/2026 (MT Newswires) -- Berenberg raised its earnings estimates for Swedish Orphan Biovitrum (SOBI.ST), or Sobi, as analysts noted the company's "excellent momentum" after the company's second-quarter results topped expectations. "Our higher forecasts reflect strong commercial momentum for key commercial assets - we now model 22% organic revenue growth in 2026," analysts said in a Friday research report. "Sobi's guidance implies a slow-down in growth in H2 to a low-double-digit percentage. However, while growth will likely slow, we think this reflects a continued degree of prudence from a management team that tends to be conservative." For the three months ended June, the biopharmaceutical company's organic revenue growth came in at 29%, which Berenberg said was "well ahead" of the 22% consensus estimate. For full-year 2026, Sobi expects revenue to grow by a mid-to high-teens percentage at constant exchange rate, against the previous guidance of low-double-digit. Subsequently, the stock's buy rating was maintained, while its price target was raised to 575 kronor from 550 kronor. The research firm's sales, EBITA, and EPS projections from 2026 through 2028 were also increased. "We think that this stock - which offers 21% 2025-30 EPS growth - is attractive, trading on 18.8x 2027E and 15.6x 2028E earnings," Berenberg added.